M
Mark M. Kockx
Researcher at University of Antwerp
Publications - 159
Citations - 12365
Mark M. Kockx is an academic researcher from University of Antwerp. The author has contributed to research in topics: Apoptosis & Macrophage. The author has an hindex of 55, co-authored 153 publications receiving 11076 citations.
Papers
More filters
Journal ArticleDOI
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Fei Su,Amaya Viros,Carla Milagre,Kerstin Trunzer,Gideon Bollag,Olivia Spleiss,Jorge S. Reis-Filho,Xiangju Kong,Richard C. Koya,Keith T. Flaherty,Paul B. Chapman,Min Jung Kim,Robert Hayward,Matthew J. Martin,Hong Yang,Qiongqing Wang,Holly Hilton,Julie S. Hang,Johannes Noe,Maryou B K Lambros,Felipe C. Geyer,Nathalie Dhomen,Ion Niculescu-Duvaz,Alfonso Zambon,Dan Niculescu-Duvaz,Natasha Preece,Lidia Robert,Nicholas Otte,Stephen Mok,Damien Kee,Yan Ma,Chao Zhang,Gaston Habets,Elizabeth A. Burton,Bernice Wong,Hoa Nguyen,Mark M. Kockx,Luc Andries,Brian Lestini,K. B. Nolop,Richard J. Lee,Andrew K. Joe,James L. Troy,Rene Gonzalez,Thomas E. Hutson,Igor Puzanov,Bartosz Chmielowski,Caroline J. Springer,Grant A. McArthur,Jeffrey A. Sosman,Roger S. Lo,Antoni Ribas,Richard Marais +52 more
TL;DR: In this article, the authors performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.
Journal ArticleDOI
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Ming-Sound Tsao,Keith M. Kerr,Mark M. Kockx,Mary Beth Beasley,Alain C. Borczuk,Johan Botling,Lukas Bubendorf,Lucian R. Chirieac,Gang Chen,Teh Ying Chou,Jin Haeng Chung,Sanja Dacic,Sylvie Lantuejoul,Mari Mino-Kenudson,Andre L. Moreira,Andrew G. Nicholson,Masayuki Noguchi,Giuseppe Pelosi,Claudia Poleri,Prudence A. Russell,Jennifer L. Sauter,Erik Thunnissen,Ignacio I. Wistuba,Hui Yu,Murry W. Wynes,Melania Pintilie,Yasushi Yatabe,Fred R. Hirsch +27 more
TL;DR: The Blueprint (BP) Programmed Death Ligand 1 (PD-L1) Immunohistochemistry Comparability Project is a pivotal academic/professional society and industrial collaboration to assess the feasibility of harmonizing the clinical use of five independently developed commercial PD-L 1 immunohistochemical assays.
Journal ArticleDOI
Phagocytosis of Apoptotic Cells by Macrophages Is Impaired in Atherosclerosis
TL;DR: It is demonstrated that phagocytosis of ACs is impaired in atherosclerotic plaques, which is at least partly attributed to oxidative stress and cytoplasmic saturation with indigestible material.
Journal ArticleDOI
Apoptosis and Related Proteins in Different Stages of Human Atherosclerotic Plaques
TL;DR: It is concluded that SMCs within human fatty streaks express BAX, which increases the susceptibility of these cells to undergo apoptosis, which could be important in the understanding of the transition of fatty streaks into atherosclerotic plaques, which are characterized by regions of cell death.
Journal ArticleDOI
Elevated Levels of Oxidative DNA Damage and DNA Repair Enzymes in Human Atherosclerotic Plaques
TL;DR: Evidence is provided that oxidative DNA damage and repair increase significantly in human atherosclerotic plaques and this is accompanied by the upregulation of DNA repair mechanisms.